DAA Therapy in Hepatitis C in Patients With Chronic Kidney Disease: New Information for GFR Category G4 and G5
We read with great interest the overview of the Kidney Disease: Improving Global Outcomes (KDIGO) guideline published in Clinical Gastroenterology and Hepatology.1 In this narrative review, the authors have presented a synopsis of the guideline, including recommendations for managment of hepatitis C virus (HCV) in patients with chronic kidney disease (CKD) focusing on the clinical aspects of using direct-acting antivirals in patients with advanced CKD (G4 and G5), those on dialysis, and kidney transplant recipients.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu Tags: Letters to the Editor Source Type: research
More News: Chia | Chronic Kidney Disease | Dialysis | Gastroenterology | Hepatitis | Hepatitis C | Kidney Transplant | Kidney Transplantation | Lung Transplant | Transplant Surgery | Transplants | Urology & Nephrology